SCYNEXIS, Inc. Presents SCY-635 Data on HCV at International Liver Congress
4/25/2013 10:21:03 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Drug discovery and development company SCYNEXIS, Inc. presented 2 studies indicating that oral treatment SCY-635 induces the production of interferon in HCV infected patients at the 48th annual meeting of the European Association for the Study of the Liver.
Help employers find you! Check out all the jobs and post your resume.
comments powered by